Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-07-05

AUTHORS

F J Giles, P D le Coutre, J Pinilla-Ibarz, R A Larson, N Gattermann, O G Ottmann, A Hochhaus, J P Radich, G Saglio, T P Hughes, G Martinelli, D-W Kim, S Novick, K Gillis, X Fan, J Cortes, M Baccarani, H M Kantarjian

ABSTRACT

Nilotinib (Tasigna) is a BCR–ABL1 tyrosine kinase inhibitor approved for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) who are newly diagnosed or intolerant of or resistant to imatinib. The 48-month follow-up data for patients with CML-CP treated with nilotinib after imatinib resistance or intolerance on an international phase II study were analyzed. Overall, 59% of patients achieved major cytogenetic response; 45% achieved complete cytogenetic response while on study. The estimated rate of overall survival (OS) and progression-free survival (PFS) at 48 months was 78% and 57%, respectively. Deeper levels of molecular responses at 3 and 6 months were highly positively correlated with long-term outcomes, including PFS and OS at 48 months. Of the 321 patients initially enrolled in the study, 98 (31%) were treated for at least 48 months. Discontinuations were primarily due to disease progression (30%) or adverse events (21%). Nilotinib is safe and effective for long-term use in responding patients with CML-CP who are intolerant of or resistant to imatinib. Further significant improvements in therapy are required for patients who are resistant or intolerant to imatinib. More... »

PAGES

107-112

Journal

TITLE

Leukemia

ISSUE

1

VOLUME

27

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/leu.2012.181

DOI

http://dx.doi.org/10.1038/leu.2012.181

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1028369333

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22763385


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imatinib Mesylate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "International Agencies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Chronic-Phase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College, Dublin, Ireland", 
          "id": "http://www.grid.ac/institutes/grid.8217.c", 
          "name": [
            "HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College, Dublin, Ireland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giles", 
        "givenName": "F J", 
        "id": "sg:person.010046107662.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010046107662.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Charit\u00e9-Humboldt-Universit\u00e4t, Campus Virchow Klinikum, Berlin, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Department of Hematology and Oncology, Charit\u00e9-Humboldt-Universit\u00e4t, Campus Virchow Klinikum, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "le Coutre", 
        "givenName": "P D", 
        "id": "sg:person.01344447222.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344447222.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA", 
          "id": "http://www.grid.ac/institutes/grid.468198.a", 
          "name": [
            "H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pinilla-Ibarz", 
        "givenName": "J", 
        "id": "sg:person.01214300454.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214300454.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Chicago, Chicago, IL, USA", 
          "id": "http://www.grid.ac/institutes/grid.170205.1", 
          "name": [
            "University of Chicago, Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Larson", 
        "givenName": "R A", 
        "id": "sg:person.011155432117.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011155432117.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gattermann", 
        "givenName": "N", 
        "id": "sg:person.01273447501.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Hematology/Oncology, University Hospital of Frankfurt, Frankfurt, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411088.4", 
          "name": [
            "Department of Medicine, Hematology/Oncology, University Hospital of Frankfurt, Frankfurt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ottmann", 
        "givenName": "O G", 
        "id": "sg:person.01051501512.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051501512.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Universit\u00e4tsklinikum Jena, Jena, Germany", 
          "id": "http://www.grid.ac/institutes/grid.275559.9", 
          "name": [
            "Department of Hematology and Oncology, Universit\u00e4tsklinikum Jena, Jena, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hochhaus", 
        "givenName": "A", 
        "id": "sg:person.01064615503.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064615503.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA", 
          "id": "http://www.grid.ac/institutes/grid.270240.3", 
          "name": [
            "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Radich", 
        "givenName": "J P", 
        "id": "sg:person.011362420057.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011362420057.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cellular Biotechnologies and Hematology, University at Orbassano, Turin, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Cellular Biotechnologies and Hematology, University at Orbassano, Turin, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saglio", 
        "givenName": "G", 
        "id": "sg:person.01334477453.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334477453.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia", 
          "id": "http://www.grid.ac/institutes/grid.414733.6", 
          "name": [
            "Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hughes", 
        "givenName": "T P", 
        "id": "sg:person.014243130677.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014243130677.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology/Oncology L and A Seragnoli, University of Bologna, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.6292.f", 
          "name": [
            "Department of Hematology/Oncology L and A Seragnoli, University of Bologna, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martinelli", 
        "givenName": "G", 
        "id": "sg:person.012171410322.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012171410322.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Seoul St Mary\u2019s Hospital, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.414966.8", 
          "name": [
            "Seoul St Mary\u2019s Hospital, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "D-W", 
        "id": "sg:person.013164724220.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013164724220.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Novick", 
        "givenName": "S", 
        "id": "sg:person.0753016076.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753016076.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gillis", 
        "givenName": "K", 
        "id": "sg:person.01021131276.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021131276.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fan", 
        "givenName": "X", 
        "id": "sg:person.01272366376.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272366376.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cortes", 
        "givenName": "J", 
        "id": "sg:person.016160407152.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016160407152.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology/Oncology L and A Seragnoli, University of Bologna, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.6292.f", 
          "name": [
            "Department of Hematology/Oncology L and A Seragnoli, University of Bologna, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baccarani", 
        "givenName": "M", 
        "id": "sg:person.01016466503.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016466503.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kantarjian", 
        "givenName": "H M", 
        "id": "sg:person.07607502677.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07607502677.73"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/leu.2012.134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042361347", 
          "https://doi.org/10.1038/leu.2012.134"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2009.38", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002899527", 
          "https://doi.org/10.1038/leu.2009.38"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm0596-561", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051513257", 
          "https://doi.org/10.1038/nm0596-561"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2010.110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016924943", 
          "https://doi.org/10.1038/leu.2010.110"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2011.323", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050607241", 
          "https://doi.org/10.1038/leu.2011.323"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2012.85", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006724216", 
          "https://doi.org/10.1038/leu.2012.85"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2008.84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024891930", 
          "https://doi.org/10.1038/leu.2008.84"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2011.355", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045865761", 
          "https://doi.org/10.1038/leu.2011.355"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-07-05", 
    "datePublishedReg": "2012-07-05", 
    "description": "Nilotinib (Tasigna) is a BCR\u2013ABL1 tyrosine kinase inhibitor approved for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) who are newly diagnosed or intolerant of or resistant to imatinib. The 48-month follow-up data for patients with CML-CP treated with nilotinib after imatinib resistance or intolerance on an international phase II study were analyzed. Overall, 59% of patients achieved major cytogenetic response; 45% achieved complete cytogenetic response while on study. The estimated rate of overall survival (OS) and progression-free survival (PFS) at 48 months was 78% and 57%, respectively. Deeper levels of molecular responses at 3 and 6 months were highly positively correlated with long-term outcomes, including PFS and OS at 48 months. Of the 321 patients initially enrolled in the study, 98 (31%) were treated for at least 48 months. Discontinuations were primarily due to disease progression (30%) or adverse events (21%). Nilotinib is safe and effective for long-term use in responding patients with CML-CP who are intolerant of or resistant to imatinib. Further significant improvements in therapy are required for patients who are resistant or intolerant to imatinib.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/leu.2012.181", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438826", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1097065", 
        "issn": [
          "0887-6924", 
          "1476-5551"
        ], 
        "name": "Leukemia", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "keywords": [
      "progression-free survival", 
      "phase II study", 
      "chronic myeloid leukemia", 
      "overall survival", 
      "CML-CP", 
      "II study", 
      "cytogenetic response", 
      "chronic phase", 
      "myeloid leukemia", 
      "Philadelphia chromosome-positive chronic myeloid leukemia", 
      "BCR-ABL1 tyrosine kinase inhibitors", 
      "international phase II study", 
      "chromosome-positive chronic myeloid leukemia", 
      "imatinib-intolerant patients", 
      "major cytogenetic response", 
      "complete cytogenetic response", 
      "long-term outcomes", 
      "treatment of patients", 
      "tyrosine kinase inhibitors", 
      "long-term use", 
      "adverse events", 
      "disease progression", 
      "imatinib resistance", 
      "patients", 
      "nilotinib", 
      "kinase inhibitors", 
      "months", 
      "leukemia", 
      "follow", 
      "further significant improvement", 
      "survival", 
      "molecular response", 
      "significant improvement", 
      "discontinuation", 
      "response", 
      "therapy", 
      "intolerance", 
      "study", 
      "progression", 
      "outcomes", 
      "treatment", 
      "inhibitors", 
      "levels", 
      "rate", 
      "events", 
      "resistance", 
      "improvement", 
      "use", 
      "data", 
      "results", 
      "phase", 
      "deep levels"
    ], 
    "name": "Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study", 
    "pagination": "107-112", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1028369333"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/leu.2012.181"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22763385"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/leu.2012.181", 
      "https://app.dimensions.ai/details/publication/pub.1028369333"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_581.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/leu.2012.181"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/leu.2012.181'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/leu.2012.181'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/leu.2012.181'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/leu.2012.181'


 

This table displays all metadata directly associated to this object as RDF triples.

393 TRIPLES      21 PREDICATES      107 URIs      91 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/leu.2012.181 schema:about N036fc5559ac24ea598ae4d64f7d92d30
2 N07917cabb4314de697a9baeea8c216ba
3 N0aad457fbe47442782c7eede4de004b0
4 N10ee8849e1024ad08c0bcfde438ab358
5 N156efb8a9a4c44d29da39edcc7615075
6 N2fba84171219466a8a87114643e1195c
7 N3431e910fd9c43fb9de448e76bddbe9a
8 N3817569531d041d1a74e5c136c9b4100
9 N3dadeed3857b42a1a3d35d946898c924
10 N465bb9566cb14d5db9671e8f4ab348c2
11 N5e3b59cb7ea640f890f763426bf0d60b
12 N65f4c1bc8e4943548654c956cb94810e
13 N68748477046b4756b08b15775de2dd13
14 N68f6bb8b19bd4d8bb28aa2dbc1fd6246
15 N829b84a9bf0a4eb288acaa494d696ba1
16 N895ac57aa37a4773aa4247658de6ec7e
17 Nb564001c85b644b0a1a03c547f50e381
18 Nd25da87ba11a4fedba529f2417db2eee
19 Ne1f3cfcdce5a4b6cbaf96a38057345e2
20 Ne27492d4033b418e97d1aa9e5dac0756
21 Ne32b95d9b793435ea7eecdc3ba6fd592
22 Nfb07900d0d4545b181a9e0a856379a90
23 anzsrc-for:11
24 anzsrc-for:1112
25 schema:author N8796981f72744c09b7d18a1673d795d3
26 schema:citation sg:pub.10.1038/leu.2008.84
27 sg:pub.10.1038/leu.2009.38
28 sg:pub.10.1038/leu.2010.110
29 sg:pub.10.1038/leu.2011.323
30 sg:pub.10.1038/leu.2011.355
31 sg:pub.10.1038/leu.2012.134
32 sg:pub.10.1038/leu.2012.85
33 sg:pub.10.1038/nm0596-561
34 schema:datePublished 2012-07-05
35 schema:datePublishedReg 2012-07-05
36 schema:description Nilotinib (Tasigna) is a BCR–ABL1 tyrosine kinase inhibitor approved for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) who are newly diagnosed or intolerant of or resistant to imatinib. The 48-month follow-up data for patients with CML-CP treated with nilotinib after imatinib resistance or intolerance on an international phase II study were analyzed. Overall, 59% of patients achieved major cytogenetic response; 45% achieved complete cytogenetic response while on study. The estimated rate of overall survival (OS) and progression-free survival (PFS) at 48 months was 78% and 57%, respectively. Deeper levels of molecular responses at 3 and 6 months were highly positively correlated with long-term outcomes, including PFS and OS at 48 months. Of the 321 patients initially enrolled in the study, 98 (31%) were treated for at least 48 months. Discontinuations were primarily due to disease progression (30%) or adverse events (21%). Nilotinib is safe and effective for long-term use in responding patients with CML-CP who are intolerant of or resistant to imatinib. Further significant improvements in therapy are required for patients who are resistant or intolerant to imatinib.
37 schema:genre article
38 schema:isAccessibleForFree false
39 schema:isPartOf N5b32fec3a32f4607a2ba7602f1d5740b
40 Nf9afd11510a548df8f0bd18c4fb90931
41 sg:journal.1097065
42 schema:keywords BCR-ABL1 tyrosine kinase inhibitors
43 CML-CP
44 II study
45 Philadelphia chromosome-positive chronic myeloid leukemia
46 adverse events
47 chromosome-positive chronic myeloid leukemia
48 chronic myeloid leukemia
49 chronic phase
50 complete cytogenetic response
51 cytogenetic response
52 data
53 deep levels
54 discontinuation
55 disease progression
56 events
57 follow
58 further significant improvement
59 imatinib resistance
60 imatinib-intolerant patients
61 improvement
62 inhibitors
63 international phase II study
64 intolerance
65 kinase inhibitors
66 leukemia
67 levels
68 long-term outcomes
69 long-term use
70 major cytogenetic response
71 molecular response
72 months
73 myeloid leukemia
74 nilotinib
75 outcomes
76 overall survival
77 patients
78 phase
79 phase II study
80 progression
81 progression-free survival
82 rate
83 resistance
84 response
85 results
86 significant improvement
87 study
88 survival
89 therapy
90 treatment
91 treatment of patients
92 tyrosine kinase inhibitors
93 use
94 schema:name Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
95 schema:pagination 107-112
96 schema:productId N2b10f37a2ffc4bbdb503e755519a5bd3
97 N6aeb543486054069943fa384f4f85772
98 Nadc196e6362944e084773dbed9135456
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028369333
100 https://doi.org/10.1038/leu.2012.181
101 schema:sdDatePublished 2022-08-04T17:00
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher Nc3b074f28aab4d9bb2d98a7fe210d870
104 schema:url https://doi.org/10.1038/leu.2012.181
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N0273293065064120b0276f062494213e rdf:first sg:person.013164724220.98
109 rdf:rest N46af1d9c0dbd4f4482032f6c1a80ff28
110 N036fc5559ac24ea598ae4d64f7d92d30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Adolescent
112 rdf:type schema:DefinedTerm
113 N07917cabb4314de697a9baeea8c216ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Imatinib Mesylate
115 rdf:type schema:DefinedTerm
116 N0aad457fbe47442782c7eede4de004b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Pyrimidines
118 rdf:type schema:DefinedTerm
119 N0b8d904d0a4c4b37b4fbd9fbb7886c7c rdf:first sg:person.01344447222.75
120 rdf:rest Nb7deb305319146cebeeeba471845aee6
121 N10ee8849e1024ad08c0bcfde438ab358 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Piperazines
123 rdf:type schema:DefinedTerm
124 N156efb8a9a4c44d29da39edcc7615075 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Aged, 80 and over
126 rdf:type schema:DefinedTerm
127 N20bbca9799404f3c96e35a934d3fe369 rdf:first sg:person.011362420057.85
128 rdf:rest N41592cec968f4730b2e6d97651eb320d
129 N21fa3b17ec994e8790a286be3175e1ca rdf:first sg:person.07607502677.73
130 rdf:rest rdf:nil
131 N2adeae4322f3431183dbc626fc67a8e1 rdf:first sg:person.016160407152.27
132 rdf:rest Na6277675c03842bd9421859b9b91c656
133 N2b10f37a2ffc4bbdb503e755519a5bd3 schema:name dimensions_id
134 schema:value pub.1028369333
135 rdf:type schema:PropertyValue
136 N2fba84171219466a8a87114643e1195c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Salvage Therapy
138 rdf:type schema:DefinedTerm
139 N3431e910fd9c43fb9de448e76bddbe9a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Male
141 rdf:type schema:DefinedTerm
142 N3817569531d041d1a74e5c136c9b4100 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Leukemia, Myeloid, Chronic-Phase
144 rdf:type schema:DefinedTerm
145 N3dadeed3857b42a1a3d35d946898c924 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Female
147 rdf:type schema:DefinedTerm
148 N41592cec968f4730b2e6d97651eb320d rdf:first sg:person.01334477453.06
149 rdf:rest Nfef0e61298a64e21a71dc0c594bb6aa3
150 N465bb9566cb14d5db9671e8f4ab348c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Prognosis
152 rdf:type schema:DefinedTerm
153 N46af1d9c0dbd4f4482032f6c1a80ff28 rdf:first sg:person.0753016076.54
154 rdf:rest Nfecf895e2997490a984111a3505d4051
155 N5b32fec3a32f4607a2ba7602f1d5740b schema:issueNumber 1
156 rdf:type schema:PublicationIssue
157 N5e3b59cb7ea640f890f763426bf0d60b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Humans
159 rdf:type schema:DefinedTerm
160 N63a9a94b5614465bb8d23a97b47b209b rdf:first sg:person.011155432117.78
161 rdf:rest Nf468a9c292d84895a56bd2df836a755a
162 N65f4c1bc8e4943548654c956cb94810e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Middle Aged
164 rdf:type schema:DefinedTerm
165 N68748477046b4756b08b15775de2dd13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Survival Rate
167 rdf:type schema:DefinedTerm
168 N68f6bb8b19bd4d8bb28aa2dbc1fd6246 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Young Adult
170 rdf:type schema:DefinedTerm
171 N6aeb543486054069943fa384f4f85772 schema:name pubmed_id
172 schema:value 22763385
173 rdf:type schema:PropertyValue
174 N7547146397454973b047d68f035aaae2 rdf:first sg:person.01272366376.65
175 rdf:rest N2adeae4322f3431183dbc626fc67a8e1
176 N829b84a9bf0a4eb288acaa494d696ba1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Adult
178 rdf:type schema:DefinedTerm
179 N8796981f72744c09b7d18a1673d795d3 rdf:first sg:person.010046107662.90
180 rdf:rest N0b8d904d0a4c4b37b4fbd9fbb7886c7c
181 N895ac57aa37a4773aa4247658de6ec7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Aged
183 rdf:type schema:DefinedTerm
184 N8e26e44bdc5640819460cd485f452e61 rdf:first sg:person.01051501512.14
185 rdf:rest Nf508883141714fd9a0968034c7aeb51f
186 Na6277675c03842bd9421859b9b91c656 rdf:first sg:person.01016466503.33
187 rdf:rest N21fa3b17ec994e8790a286be3175e1ca
188 Nadc196e6362944e084773dbed9135456 schema:name doi
189 schema:value 10.1038/leu.2012.181
190 rdf:type schema:PropertyValue
191 Nb564001c85b644b0a1a03c547f50e381 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Drug Resistance, Neoplasm
193 rdf:type schema:DefinedTerm
194 Nb7deb305319146cebeeeba471845aee6 rdf:first sg:person.01214300454.43
195 rdf:rest N63a9a94b5614465bb8d23a97b47b209b
196 Nc3b074f28aab4d9bb2d98a7fe210d870 schema:name Springer Nature - SN SciGraph project
197 rdf:type schema:Organization
198 Nd25da87ba11a4fedba529f2417db2eee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Maximum Tolerated Dose
200 rdf:type schema:DefinedTerm
201 Ne1f3cfcdce5a4b6cbaf96a38057345e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Follow-Up Studies
203 rdf:type schema:DefinedTerm
204 Ne27492d4033b418e97d1aa9e5dac0756 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name International Agencies
206 rdf:type schema:DefinedTerm
207 Ne32b95d9b793435ea7eecdc3ba6fd592 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Benzamides
209 rdf:type schema:DefinedTerm
210 Nf06ad97f22f44c3b9b7efccb6759cff9 rdf:first sg:person.012171410322.93
211 rdf:rest N0273293065064120b0276f062494213e
212 Nf468a9c292d84895a56bd2df836a755a rdf:first sg:person.01273447501.34
213 rdf:rest N8e26e44bdc5640819460cd485f452e61
214 Nf508883141714fd9a0968034c7aeb51f rdf:first sg:person.01064615503.48
215 rdf:rest N20bbca9799404f3c96e35a934d3fe369
216 Nf9afd11510a548df8f0bd18c4fb90931 schema:volumeNumber 27
217 rdf:type schema:PublicationVolume
218 Nfb07900d0d4545b181a9e0a856379a90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Protein Kinase Inhibitors
220 rdf:type schema:DefinedTerm
221 Nfecf895e2997490a984111a3505d4051 rdf:first sg:person.01021131276.58
222 rdf:rest N7547146397454973b047d68f035aaae2
223 Nfef0e61298a64e21a71dc0c594bb6aa3 rdf:first sg:person.014243130677.65
224 rdf:rest Nf06ad97f22f44c3b9b7efccb6759cff9
225 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
226 schema:name Medical and Health Sciences
227 rdf:type schema:DefinedTerm
228 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
229 schema:name Oncology and Carcinogenesis
230 rdf:type schema:DefinedTerm
231 sg:grant.2438826 http://pending.schema.org/fundedItem sg:pub.10.1038/leu.2012.181
232 rdf:type schema:MonetaryGrant
233 sg:journal.1097065 schema:issn 0887-6924
234 1476-5551
235 schema:name Leukemia
236 schema:publisher Springer Nature
237 rdf:type schema:Periodical
238 sg:person.010046107662.90 schema:affiliation grid-institutes:grid.8217.c
239 schema:familyName Giles
240 schema:givenName F J
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010046107662.90
242 rdf:type schema:Person
243 sg:person.01016466503.33 schema:affiliation grid-institutes:grid.6292.f
244 schema:familyName Baccarani
245 schema:givenName M
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016466503.33
247 rdf:type schema:Person
248 sg:person.01021131276.58 schema:affiliation grid-institutes:grid.418424.f
249 schema:familyName Gillis
250 schema:givenName K
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021131276.58
252 rdf:type schema:Person
253 sg:person.01051501512.14 schema:affiliation grid-institutes:grid.411088.4
254 schema:familyName Ottmann
255 schema:givenName O G
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051501512.14
257 rdf:type schema:Person
258 sg:person.01064615503.48 schema:affiliation grid-institutes:grid.275559.9
259 schema:familyName Hochhaus
260 schema:givenName A
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064615503.48
262 rdf:type schema:Person
263 sg:person.011155432117.78 schema:affiliation grid-institutes:grid.170205.1
264 schema:familyName Larson
265 schema:givenName R A
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011155432117.78
267 rdf:type schema:Person
268 sg:person.011362420057.85 schema:affiliation grid-institutes:grid.270240.3
269 schema:familyName Radich
270 schema:givenName J P
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011362420057.85
272 rdf:type schema:Person
273 sg:person.01214300454.43 schema:affiliation grid-institutes:grid.468198.a
274 schema:familyName Pinilla-Ibarz
275 schema:givenName J
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214300454.43
277 rdf:type schema:Person
278 sg:person.012171410322.93 schema:affiliation grid-institutes:grid.6292.f
279 schema:familyName Martinelli
280 schema:givenName G
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012171410322.93
282 rdf:type schema:Person
283 sg:person.01272366376.65 schema:affiliation grid-institutes:grid.418424.f
284 schema:familyName Fan
285 schema:givenName X
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272366376.65
287 rdf:type schema:Person
288 sg:person.01273447501.34 schema:affiliation grid-institutes:grid.411327.2
289 schema:familyName Gattermann
290 schema:givenName N
291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34
292 rdf:type schema:Person
293 sg:person.013164724220.98 schema:affiliation grid-institutes:grid.414966.8
294 schema:familyName Kim
295 schema:givenName D-W
296 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013164724220.98
297 rdf:type schema:Person
298 sg:person.01334477453.06 schema:affiliation grid-institutes:None
299 schema:familyName Saglio
300 schema:givenName G
301 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334477453.06
302 rdf:type schema:Person
303 sg:person.01344447222.75 schema:affiliation grid-institutes:grid.6363.0
304 schema:familyName le Coutre
305 schema:givenName P D
306 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344447222.75
307 rdf:type schema:Person
308 sg:person.014243130677.65 schema:affiliation grid-institutes:grid.414733.6
309 schema:familyName Hughes
310 schema:givenName T P
311 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014243130677.65
312 rdf:type schema:Person
313 sg:person.016160407152.27 schema:affiliation grid-institutes:grid.240145.6
314 schema:familyName Cortes
315 schema:givenName J
316 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016160407152.27
317 rdf:type schema:Person
318 sg:person.0753016076.54 schema:affiliation grid-institutes:grid.418424.f
319 schema:familyName Novick
320 schema:givenName S
321 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753016076.54
322 rdf:type schema:Person
323 sg:person.07607502677.73 schema:affiliation grid-institutes:grid.240145.6
324 schema:familyName Kantarjian
325 schema:givenName H M
326 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07607502677.73
327 rdf:type schema:Person
328 sg:pub.10.1038/leu.2008.84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024891930
329 https://doi.org/10.1038/leu.2008.84
330 rdf:type schema:CreativeWork
331 sg:pub.10.1038/leu.2009.38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002899527
332 https://doi.org/10.1038/leu.2009.38
333 rdf:type schema:CreativeWork
334 sg:pub.10.1038/leu.2010.110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016924943
335 https://doi.org/10.1038/leu.2010.110
336 rdf:type schema:CreativeWork
337 sg:pub.10.1038/leu.2011.323 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050607241
338 https://doi.org/10.1038/leu.2011.323
339 rdf:type schema:CreativeWork
340 sg:pub.10.1038/leu.2011.355 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045865761
341 https://doi.org/10.1038/leu.2011.355
342 rdf:type schema:CreativeWork
343 sg:pub.10.1038/leu.2012.134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042361347
344 https://doi.org/10.1038/leu.2012.134
345 rdf:type schema:CreativeWork
346 sg:pub.10.1038/leu.2012.85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006724216
347 https://doi.org/10.1038/leu.2012.85
348 rdf:type schema:CreativeWork
349 sg:pub.10.1038/nm0596-561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051513257
350 https://doi.org/10.1038/nm0596-561
351 rdf:type schema:CreativeWork
352 grid-institutes:None schema:alternateName Department of Cellular Biotechnologies and Hematology, University at Orbassano, Turin, Italy
353 schema:name Department of Cellular Biotechnologies and Hematology, University at Orbassano, Turin, Italy
354 rdf:type schema:Organization
355 grid-institutes:grid.170205.1 schema:alternateName University of Chicago, Chicago, IL, USA
356 schema:name University of Chicago, Chicago, IL, USA
357 rdf:type schema:Organization
358 grid-institutes:grid.240145.6 schema:alternateName Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
359 schema:name Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
360 rdf:type schema:Organization
361 grid-institutes:grid.270240.3 schema:alternateName Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
362 schema:name Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
363 rdf:type schema:Organization
364 grid-institutes:grid.275559.9 schema:alternateName Department of Hematology and Oncology, Universitätsklinikum Jena, Jena, Germany
365 schema:name Department of Hematology and Oncology, Universitätsklinikum Jena, Jena, Germany
366 rdf:type schema:Organization
367 grid-institutes:grid.411088.4 schema:alternateName Department of Medicine, Hematology/Oncology, University Hospital of Frankfurt, Frankfurt, Germany
368 schema:name Department of Medicine, Hematology/Oncology, University Hospital of Frankfurt, Frankfurt, Germany
369 rdf:type schema:Organization
370 grid-institutes:grid.411327.2 schema:alternateName Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine-Universität, Düsseldorf, Germany
371 schema:name Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine-Universität, Düsseldorf, Germany
372 rdf:type schema:Organization
373 grid-institutes:grid.414733.6 schema:alternateName Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
374 schema:name Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
375 rdf:type schema:Organization
376 grid-institutes:grid.414966.8 schema:alternateName Seoul St Mary’s Hospital, Seoul, Korea
377 schema:name Seoul St Mary’s Hospital, Seoul, Korea
378 rdf:type schema:Organization
379 grid-institutes:grid.418424.f schema:alternateName Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
380 schema:name Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
381 rdf:type schema:Organization
382 grid-institutes:grid.468198.a schema:alternateName H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
383 schema:name H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
384 rdf:type schema:Organization
385 grid-institutes:grid.6292.f schema:alternateName Department of Hematology/Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
386 schema:name Department of Hematology/Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
387 rdf:type schema:Organization
388 grid-institutes:grid.6363.0 schema:alternateName Department of Hematology and Oncology, Charité-Humboldt-Universität, Campus Virchow Klinikum, Berlin, Germany
389 schema:name Department of Hematology and Oncology, Charité-Humboldt-Universität, Campus Virchow Klinikum, Berlin, Germany
390 rdf:type schema:Organization
391 grid-institutes:grid.8217.c schema:alternateName HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College, Dublin, Ireland
392 schema:name HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College, Dublin, Ireland
393 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...